Association between prescribing of antimuscarinic drugs and antimuscarinic adverse effects in older people

Expert Review of Clinical Pharmacology

Volumn 3, Issue 4, 2010, Pages 441-452

  Bostock, Clare V ^a   Soiza, Roy L ^a   Mangoni, Arduino A ^a,b,c  

^a WOODEND HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

adverse drug reactions; anticholinergic drugs; antimuscarinic drugs; drug safety; elderly patients; prescribing

Indexed keywords

AMITRIPTYLINE; AMOXICILLIN; ATROPINE; CHLORPHENIRAMINE MALEATE; CHLORPROMAZINE; CHOLINESTERASE INHIBITOR; CITALOPRAM; CLOZAPINE; DICYCLOVERINE; DIGOXIN; DOSULEPIN; FLUOXETINE; HALOPERIDOL; HYDROXYZINE; IPRATROPIUM BROMIDE; METFORMIN; MUSCARINIC RECEPTOR BLOCKING AGENT; OLANZAPINE; OXYBUTYNIN; PROCHLORPERAZINE; PROCYCLIDINE; RANITIDINE; SCOPOLAMINE; SCOPOLAMINE BROMIDE; SCOPOLAMINE BUTYL BROMIDE; TIOTROPIUM BROMIDE; TOLTERODINE; TRIHEXYPHENIDYL; TROPICAMIDE; UNINDEXED DRUG;

ADVERSE OUTCOME; AGITATION; AMNESIA; ANTICHOLINERGIC EFFECT; ATTENTION DISTURBANCE; BRADYCARDIA; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; CORRELATIONAL STUDY; DATA COLLECTION METHOD; DELIRIUM; DEMENTIA; DISORIENTATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE INCREASE; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; FALLING; GASTROINTESTINAL HEMORRHAGE; GENETIC SUSCEPTIBILITY; GERIATRIC PATIENT; GLOMERULUS FILTRATION RATE; HALLUCINATION; HIGH RISK PATIENT; HUMAN; IRRITABLE COLON; MEMORY DISORDER; METHODOLOGY; MILD COGNITIVE IMPAIRMENT; MOTION SICKNESS; MYDRIASIS; NONHUMAN; OVERACTIVE BLADDER; PARKINSON DISEASE; PERISTALSIS; POLYPHARMACY; PRESCRIPTION; PSYCHOMOTOR DISORDER; RESPIRATORY TRACT DISEASE; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE; SIDE EFFECT; SWEATING; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; URINE RETENTION; VISUAL DISORDER; XEROSTOMIA;

EID: 77954890671     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.10.34     Document Type: Review

References (72)

1. Rang HP, Dale MM, Ritter JM, Flower RJ. Cholinergic transmission. In: Rang and Dale's Pharmacology (6th Edition). Churchill Livingstone, Edinburgh, UK 144-167 (2007).
2. Westfall TC, Westfall DP. Neurotransmission: the autonomic and somatic motor nervous systems. In: Goodman and Gilman s The Pharmacological Basis of Therapeutics (11th Edition). McGraw Hill, NY, USA 137-181 (2006).
3. Brown JH, Taylor P. Muscarinic receptor agonists and antagonists. In: Goodman and Gilman's the Pharmacological Basis of Therapeutics (11th Edition). McGraw Hill, NY, USA 183-216 (2006).
4. Peters NL. Snipping the thread of life: antimuscarinic side effects of medications in the elderly. Arch. Intern. Med. 149, 2414-2420 (1989).
5. Montastruc JL, Durrieu G, Sommet A, Damase-Michel C, Lapeyre-Mestre M. Anticholinergics, antimuscarinics or atropinics? About the words in pharmacology. Br. J. Clin. Pharmacol. 73(6), 629-632 (2006).
6. Greenblatt DJ, Shader RI. Drug therapy: anticholinergics. N. Engl. J. Med. 288(23), 1215-1219 (1973).
7. British National Formulary (59th Edition). BMJ Group and Pharmaceutical Press, London, UK (2010).
8. Alhasso AA, McKinlay J, Patrick K, Stewart L. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst. Rev. (4), CD003193 (2006).
9. Nabi G, Cody JD, Ellis G, Hay-Smith J, Herbison GP. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst. Rev. (4), CD003781 (2006).
10. McCrory DC, Brown CD. Anticholinergic bronchodilators versus β2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. (1), CD003900 (2006).
11. Barr RG, Bourbeau J, Camargo CA. Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. (2), CD002876 (2005).
12. Lee TA, Wilke C, Joo M et al. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. Arch. Intern. Med. 169(15), 1403-1410 (2009).
13. Quartero AO, Meiniche-Schmidt V, Muris J, Rubin G, de Wit N. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst. Rev. (2), CD003460 (2005).
14. Lawson F, Jethwa K, Silva de Lima M, Soares B, Galapatthie N. Anticholinergics for neuroleptic-induced parkinsonism. Cochrane Database Syst. Rev. (2), CD005964 (2006).
15. Chew ML, Mulsant BH, Pollock BG et al. Anticholinergic activity of 107 medications commonly used by older adults. J. Am. Geriatr. Soc. 56, 1333-1341 (2008).
16. Mulsant BH, Pollock BG, Kirshner M, Shen C, Dodge H, Ganguli M. Serum anticholinergic activity in a community- based sample of older adults: relationship with cognitive performance. Arch. Gen. Psychiatry 60, 198-203 (2003).
17. Carriere I, Fourrier-Reglat A, Dartigues JF et al. Drugs with anticholinergic properties, cognitive decline and dementia in an elderly general population: the 3-City study. Arch. Intern. Med. 169(14), 1317-1324 (2009).
18. Parasca A, Doogue MP, Woodman RJ, Mangoni AA. Hypoalbuminaemia and impaired renal function are associated with increased anticholinergic drug prescribing. Int. J. Clin. Pract. 63(7), 1110-1114 (2009).
19. Lechevallier-Michel N, Molimard M, Dartigues JF, Fabrigoule C, Fourrier- Reglat A. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID study. Br. J. Clin. Pharamol. 59(2), 143-151 (2005).
20. Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin. DrugMetab. Toxicol. 4(8), 1065-1074 (20 08).
21. Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging 3, 335-348 (1993).
22. Popescu BO, Toescu EC, Popescu LM et al. Blood-brain barrier alterations in ageing and dementia. J. Neurosci. 283, 99-106 (2009).
23. Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease - systematic review and meta- analysis. Neurobiol. Aging 30, 337-352 (2009).
24. Bauer M, Karch R, Neumann F et al. Age dependency of cerebral P-gp function measured with (R)-[nC]verapamil and PET. Eur. J. Clin. Pharmacol. 65, 941-946
25. Kay GG, Abou-Donia MB, Messer WS, Murphy DG, Tsao JW, Ouslander JG. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J. Am. Geriatr. Soc. 53, 2195-2201 (2005).
26. Bartels AL, Kortekaas R, Bart J et al. Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol. Aging 30, 1818-1824 (2009).
27. Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The Anticholinergic Risk Scale and anticholinergic adverse effects in older persons. Arch. Intern. Med. 168(5), 508-513 (2008).
28. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron 63(3), 287-303 (2009).
29. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10(5), 333-344 (2009).
30. Querfurth HW, LaFerla FM. Alzheimer s disease. N. Engl. J. Med. 362(4), 329-344
31. Henderson VE. On the sensitivity of different nerve endings to atropine. J. Pharmacol. Exp. Ther. 21, 99-102 (1923).
32. Ursillo. Investigation of certain aspects of atropine-resistant nerve effects. J. Pharmaol. Exp. Ther. 131(2), 231-236 (1961).
33. Herxheimer A. A comparison of some atropine-like drugs in man, with particular reference to their end-organ specificity. Br. J. Pharmacol. 13, 184-192 (1958).
34. Arroll B, Elley CR, Fishman T et al. Antidepressants versus placebo for depression in primary care. Cochrane Database Syst. Rev. (3), CD007954 (2009).
35. Hilmer SN, Mager DE, Simonsick EM et al. A Drug Burden Index to define the functional burden of medications in older people. Arch. Intern. Med. 167, 781-787 (2007).
36. Flacker JM, Wei JY. Endogenous anticholinergic substances may exist during acute illness in elderly medical patients. J. Gerontol. Med. Sci. 56A, M353-M355 (2001).
37. Tune L, Coyle JT. Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects. Arch. Gen. Psychiatry 37, 293-297 (1980).
38. Tune L, Coyle JT. Acute extrapyramidal side effects: serum levels of neuroleptics and anticholinergics. Psychopharmacology 75, 9-15 (1981). (Pubitemid 11020938)
39. Nebes RD, Pollock BG, Hallidan EM, Kirshner MA, Houck PR. Serum anticholinergic activity and motor performance in elderly persons. J. Geronotol. Med. Sci. 62A, 83-85 (2007).
40. Chew ML, Mulsant BH, Pollock NG et al. A model of anticholinergic activity of atypical antipsychotic medications. Schizophr. Res. 88, 63-72 (2006).
41. Carnahan RM, Lund BC, Perry PJ, Pollock BG. A critical appraisal of the utility of the serum anticholinergic activity assay in research and clinical practice. Psychopharamcol. Bull. 36(2), 24-39 (2002).
42. Han L, Agostini JV, Allore HG. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J. Am. Geriatr. Soc. 56, 2203-2210 (2008).
43. Kwatra M. Limitations of the Anticholinergic Risk Scale. Arch. Intern. Med. 168, 2386 (2008).
44. Hilmer SN, Abernethy DR. Measures of drug toxicity in older adults. Arch. Intern. Med. 168, 1930-1931 (2008).
45. Nishtala PS, Fois RA, McLaclan AJ et al. Anticholinergic activity of commonly prescribed medications and neuropsychiatric adverse events in older people. J. Clin. Pharmacol. 49, 1176-1184 (2009).
46. Cao YJ, Mager DE, Simonsick EM et al. Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older women. Clin. Pharmacol. Ther. 83(3), 422-429 (2008).
47. Agostini JV, Han L, Tinetti ME. The relationship between number of medications and weight loss or impaired balance in older adults. J. Am. Geriatr. Soc. 52, 1719-1723 (2004).
48. Alarcon T, Barcena A, Gonzalez- Montalvo JI, Penalosa C, Salgado A. Factors predictive of outcome on admission to an acute geriatric ward. Age Ageing 28, 429-432 (1999).
49. Campbell SE, Seymour DG, Primrose WR; for the ACME plus project. A systematic literature review of factors affecting outcome in older medical patients admitted to hospital. Age Ageing 33, 110-115 (2004).
50. Gnjidic J, Cumming RG, Le Couteur DG et al. Drug Burden Index and physical function in older Australian men. Br. J. Clin. Pharmaol. 68(1), 97-105 (2009).
51. Nishtala PS, Hilmer SN, McLachlan AJ, Hannan PJ, Chen TF. Impact of residential medication management reviews on Drug Burden Index in aged-care homes: a retrospective analysis. Drugs Aging 26, 677-686 (2009).
52. Hilmer SN, Mager DE, Simonsick EM et al. Drug Burden Index score and functional decline in older people. Am. J. Med. 122, 1142-1149 (2009).
53. Flicker C, Serby M, Ferris SH. Scopolamine effects on memory, language, visuospatial praxis and psychomotor speed. Psychopharmacology (Berl.) 100, 243-250 (1990).
54. Molchan SE, Martinez RA, Hill JL et al. Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res. Rev. 1992(17), 215-226 (1992).
55. Flicker C, Ferris SH, Serby M. Hypersensitivity to scopolamine in the elderly. Psychopharmacology (Berl.) 107, 437-441 (1992).
56. Laroche ML, Charmes JP, Nouaille Y, Picard N, Merle L. Is inappropriate medication use a major cause of adverse drug reactions in the elderly? Br. J. Clin. Pharmacol. 63(2), 177-186 (2006).
57. Wester K, Jonsson AK, Spigset O, Druid H, Hagg S. Incidence of fatal adverse drug reactions: a population based study. Br. J. Clin. Pharmacol. 65(4), 573-579 (2007).
58. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MK. Studies of illness in the aged: in index of ADL a standardized measure of biological and psychosocial function. JAMA 185, 914-919 (1963).
59. Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ 315, 1096-1099 (1997).
60. Gill SS, Mamdani M, Naglie G et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch. Intern. Med. 165, 808-813 (2005).
61. Hashimoto M, Imamura T, Tanimukai S, Kazui H, Mori E. Urinary incontinence: an unrecognised adverse effect with donepezil. Lancet 356, 568 (2000).
62. Edwards KR, O'Connor JT. Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors. J. Am. Geriatr. Soc. 50(6), 1165-1166 (2002).
63. Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, Ritchie K. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 332, 455-459 (2006).
64. Chew ML, Mulsant BH, Pollock BG. Serum anticholinergic activity and cognition in patients with moderate-to- severe dementia. Am. J. Geriatr. Psychiatry 13(6), 535-538 (2005).
65. Agostini JV. Measuring drug burden: a step forward. Arch. Intern. Med. 167, 753-754 (2007).
66. George CF , Robertson D. Clinical consequences of abrupt drug withdrawal. Med. Toxicol. Adverse Drug Exp. 2(5), 367-382 (1987).
67. Friedman MJ, Jaffe JH, Sharpless SK. Central nervous system supersensitivity to pilocarpine after withdrawal of chronically administered scopolamine. J. Pharmacol. Exp. Ther. 167(1), 45-55 (1969).
68. Luchins DJ, Freed WJ, Wyatt RJ. The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs. Am. J. Psychiatry 137(11), 1395-1398 (1980).
69. Newcomb R, Tashkin DP, Hui KK, Conolly ME, Lee E, Dauphinee B. Rebound hyperresponsiveness to muscarinic stimulation after chronic therapy with an inhaled muscarinic antagonist. Am. Rev. Respir. Dis. 132(1), 12-15 (1985).
70. Shiovitz TM, Welke TL, Tigel PD et al. Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal. Schizophr. Bull. 22(4), 591-595 (1996).
71. Fries JF. Aging, natural death, and the compression of morbidity. N. Engl. J. Med. 303, 130-135 (1980).
72. Gurwitz JH, Avorn J. The ambiguous relation between aging and adverse drug reactions. Ann. Intern. Med. 114, 956-966 (1991).